News

News 10.12.2020 Schlieren and St. Gallen, Switzerland, December 10, 2020 - The Center for Laboratory Medicine in St. Gallen and Proteomedix, the Swiss cancer diagnostics company, announced that Prof. Dr. med. Wolfang Korte who leads the Center for Laboratory Medicine will present new data from the implementation of Proclarix® in their laboratory...

News 02.12.2020 Zurich-Schlieren, Switzerland and Frankfurt am Main, Germany, December 2, 2020 - The University Hospital Frankfurt MVZ (Medical Outpatient Care Center) GmbH, and Proteomedix, the Swiss cancer diagnostics company, announced today that Proclarix®, a new blood-based test for prostate cancer patient management, is made routinely available in Germany. ”Proclarix is an innovative...

Events, External events
Event date: 09.12.2020 9 December 2020 from 12.00-13.00 CET Are you an entrepreneur in the life sciences, pharma or healthcare industry and do you aim to attract external funding to develop and grow your business? Or has your company already completed a series A investment and are you ready for the next investment round...

News 23.11.2020 Zurich-Schlieren, Switzerland, November 23, 2020. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that a first cohort of eight healthy volunteers has been dosed in a Phase 1 first-in-human study of MP0420 (ensovibep),...

Events, Internal events
Event date: 15.12.2020 Dienstag, 15. Dezember 2020, 12:00h – 13:00h Viele Unternehmen nutzen die Vorteile der Steuerreform NICHT – gehört Ihr Unternehmen auch dazu? Die Patentbox bietet für Unternehmen mit Immaterialgüterrechten die Möglichkeit die Gewinnsteuern massiv zu senken. Mit dem Zusatzabzug für Forschung & Entwicklung erhalten Unternehmen einen «Zustupf» an deren Entwicklungskosten. Auch wenn bei...